High-risk HR+, HER2- EBC: Patient ID & Tailoring Treatment for Community Oncologists

Join Medical Oncologist, Naomi Dempsey, of Baptist Health Cancer Center as she shares clinical data and insights for community oncologists in identifying and optimizing treatment for patients with high-risk HR+, HER2- Early Breast Cancer.

After viewing this webinar, community oncologists will be able to:

Explain the risk of disease recurrence and how this can guide treatment strategies
Assess which patients may benefit from the addition of a CDK4/6 inhibitor and formulate individualized treatment plans to optimize treatment selection
Formulate strategies to anticipate and manage adverse events associated with CDK4/6 inhibitors to support treatment adherence and maximize clinical outcomes

Agenda

Assessing risk to identify patients with HR+, HER2- EBC who are at a higher risk of recurrence
Implementing evidence in everyday clinical practice
Patient management strategies to maximize adherence and persistence

Post-webinar Quiz—Check Your Knowledge

For patients with HR+, HER2- EBC with a higher risk of recurrence , based on clinical features, when can a peak of recurrences be observed during adjuvant ET?

6 Months

2 Years

3-5 Years

5+ Years

A 56-year-old patient noticed a lump in her right breast. Ultrasound revealed a 2cm solid mass. Core needle biopsy was positive for invasive ductal carcinoma and biopsy showed ER+ 90%, PR 20%, HER2-, Grade 3. One positive ALN was also detected. Based on this limited information how would you classify this patient’s risk of recurrence?

Low

Intermediate

High

Cannot be determined

A 38 year old pre-menopausal woman presents with HR+, HER2- stage 3 EBC. Clinical features include 3 positive ALNs and a 4cm tumor. What would be your consideration for adjuvant therapy?

ET alone

Tamoxifen + CDK4/6 Inhibitor

ET + LHRH antagonist + CDK4/6 Inhibitor

Other